Seer (NASDAQ:SEER) CFO Sells $12,342.07 in Stock

Seer, Inc. (NASDAQ:SEER) CFO David Horn sold 7,303 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $1.69, for a total transaction of $12,342.07. Following the completion of the transaction, the chief financial officer owned 493,959 shares of the company’s stock, valued at $834,790.71. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seer Stock Up 1.1%

Shares of SEER opened at $1.79 on Friday. The firm has a 50-day moving average price of $1.80 and a 200 day moving average price of $1.87. The firm has a market capitalization of $100.99 million, a PE ratio of -1.44 and a beta of 1.63. Seer, Inc. has a 52-week low of $1.65 and a 52-week high of $2.41.

Seer (NASDAQ:SEER) last announced its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million.

Analyst Upgrades and Downgrades

SEER has been the subject of several research reports. Canaccord Genuity Group initiated coverage on shares of Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price objective for the company. TD Cowen upgraded shares of Seer to a “strong-buy” rating in a report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $4.00.

Institutional Trading of Seer

Hedge funds have recently made changes to their positions in the stock. Occudo Quantitative Strategies LP purchased a new stake in shares of Seer in the second quarter worth approximately $25,000. Marshall Wace LLP purchased a new stake in shares of Seer in the fourth quarter worth approximately $85,000. Quadrature Capital Ltd purchased a new stake in shares of Seer in the fourth quarter worth approximately $101,000. Barclays PLC lifted its position in shares of Seer by 685.0% in the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after purchasing an additional 52,982 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Seer during the fourth quarter valued at approximately $116,000. 75.20% of the stock is owned by hedge funds and other institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.